| 注册
首页|期刊导航|中国组织工程研究|减低剂量预处理方案在亲缘HLA单倍体相合造血干细胞移植中的应用

减低剂量预处理方案在亲缘HLA单倍体相合造血干细胞移植中的应用

杨廷 江明

中国组织工程研究Issue(6):955-961,7.
中国组织工程研究Issue(6):955-961,7.DOI:10.3969/j.issn.2095-4344

减低剂量预处理方案在亲缘HLA单倍体相合造血干细胞移植中的应用

Reduced-intensity conditioning regimen in HLA-haploidentical hematopoietic stem cell transplantation

杨廷 1江明2

作者信息

  • 1. 新疆医科大学第一附属医院,新疆维吾尔自治区乌鲁木齐市 830054
  • 2. 新疆医科大学第一附属医院血液病中心,新疆维吾尔自治区血液病研究所,新疆维吾尔自治区乌鲁木齐市 830054
  • 折叠

摘要

Abstract

BACKGROUND:Reduced-intensity conditioning alogeneic hematopoietic stem cel transplantation (RIC-alo-HSCT) is proved being one of the effective methods to cure hematologic malignancies recently, which has been used more and more in patients with matched sibling or matched unrelated donor year by year. It is more suitable for elderly patients or younger patients combined with any organ dysfunction or complications. However, matched sibling and matched unrelated donors are not easy to be obtained for RIC-alo-HSCT. While HLA-haploidentical donor can be quickly found in family members for the patients who need receiving RIC-alo-HSCT. Fewer papers for reduced-intensity conditioning haploidentical hematopoietic stem cel transplantation (RIC-haplo-HSCT) have been reported in the world, and none in China, so the review for RIC-haplo-HSCT is necessary. OBJECTIVE:To reveiw the application of RIC-haplo-HSCT and its prospect. METHODS:Using “nonmyeloablative conditioning, reduced intensity conditioning, HLA-haploidentical, hematopoietic stem cel transplantation” as key words, we retrieved Wanfang, CNKI and PubMed databases, and foreign language search platform (1997-2014) by computer for literatures about RIC-haplo-HSCT. According to the inclusion and exclusion criteria, 25 articles in English were selected for our review ultimately. RESULTS AND CONCLUSION: This review shows that RIC-alo-HSCT with matched sibling and matched unrelated donor is widely used and has a better result increasingly. RIC-haplo-HSCT is carried out relatively late and less, and its engraftment, infection, transplant-related mortality, graft-versus-host disease, long-term disease-free survival and overal survival in the early period is a bit weak, but overal the situation has been recently improved significantly. Currently RIC-haplo-HSCT is feasible, especialy for patients lack of matched sibling donor and matched unrelate donor, and HLA haploidentical donor becomes the most potential source of hematopoietic stem cels. RIC-haplo-HSCT retains strong graft-versus-leukemia effect, and is easy to look for donor, as wel as there are sufficient cels for subsequent treatments such as donor lymphocyte infusion, which through a graft-versus-leukemia effect can eliminate the patient’s malignant cels, especialy for elderly patients and younger patients combined with any organ dysfunction or complications. However, due to the relative short time to carry out RIC-haplo-HSCT, how to choice optimal RIC regimen and optimal opportunity and how to reduce transplant-related mortality, graft-versus-host disease and relapse rate require further in-depth studies.

关键词

干细胞/移植/异基因造血干细胞移植/减低剂量预处理/亲缘HLA不相合/单倍体相合/移植物抗宿主病

Key words

Subject headings:Hematopoietic Stem Cel Transplantation/Transplantation Conditioning/Graft vs Host Disease

分类

医药卫生

引用本文复制引用

杨廷,江明..减低剂量预处理方案在亲缘HLA单倍体相合造血干细胞移植中的应用[J].中国组织工程研究,2015,(6):955-961,7.

基金项目

新疆维吾尔自治区高新技术项目(201317104)Funding:the High-Tech Projects of Xinjiang Uygur Autonomous Region, No.201317104 (201317104)

中国组织工程研究

OA北大核心CSTPCD

2095-4344

访问量0
|
下载量0
段落导航相关论文